Literature DB >> 679592

Clinically significant adverse effects in a Phase 1 testing program.

C J Zarafonetis, P A Riley, P W Willis, L H Power, J Werbelow, L Farhat, W Beckwith, B H Marks.   

Abstract

Twelve years' experience with a Phase I drug testing program in normal prison volunteers is reported. Involved in 805 protocol studies were 29,162 participants over 614,534 subject days. During this period there were 64 significant medical events of which 58 were adverse drug reactions and 6 were complications. One subject has residual hip changes due to an infectious complication, another on placebo died from cerebrovascular hemorrhage while asleep. There was complete recovery from all adverse drug reactions and the other 4 complications encountered. Thus a clinically significant medical event occurred once every 9,602 days subject exposure or about once every 26.3 years of individual subject participation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679592     DOI: 10.1002/cpt1978242127

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Adverse events in phase one studies: a study in 430 healthy volunteers.

Authors:  M Sibille; N Deigat; V Olagnier; D V Durand; R Levrat
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Weight of financial reward in the decision by medical students and experienced healthy volunteers to participate in clinical trials.

Authors:  J Bigorra; J E Baños
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors:  Adam Cohen
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Sensation seeking amongst healthy volunteers participating in phase I clinical trials.

Authors:  M Farré; X Lamas; J Camí
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  When a serious adverse event in research occurs, how do other volunteers react?

Authors:  Caitlin E Kennedy; Nancy Kass; Rachel K Myers; Edward J Fuchs; Charles Flexner
Journal:  J Empir Res Hum Res Ethics       Date:  2011-06       Impact factor: 1.742

6.  Drug lag bad: drug lack worse.

Authors: 
Journal:  Br Med J       Date:  1980-03-08

7.  [Drug safety: activities of the manufacturer].

Authors:  P Krupp
Journal:  Soz Praventivmed       Date:  1980-03

8.  Payment to healthy volunteers in clinical research: the research subject's perspective.

Authors:  M J Czarny; N E Kass; C Flexner; K A Carson; R K Myers; E J Fuchs
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

9.  Patient attitudes following participation in a health outcome survey.

Authors:  D P Funch; J R Marshall
Journal:  Am J Public Health       Date:  1981-12       Impact factor: 9.308

10.  Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.

Authors:  Ivo P Nnane; Alexei H Plotnikov; Gary Peters; Maureen Johnson; Clare Kojak; Apinya Vutikullird; Jay Ariyawansa; Ronald De Vries; Brian E Davies
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.